Kazakhstan

Population 2018 18 million

<table>
<thead>
<tr>
<th>Estimates of TB burden, 2018</th>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>12 (8.1–18)</td>
<td>68 (44–97)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>0.73 (0.47–1)</td>
<td>4 (2.6–5.7)</td>
</tr>
<tr>
<td>MDR/RR-TB incidence</td>
<td>4.8 (3–6.9)</td>
<td>26 (16–38)</td>
</tr>
<tr>
<td>HIV-negative TB mortality</td>
<td>0.43 (0.36–0.51)</td>
<td>2.3 (1.9–2.8)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>0.048 (0.014–0.1)</td>
<td>0.26 (0.08–0.56)</td>
</tr>
</tbody>
</table>

Estimated proportion of TB cases with MDR/RR-TB, 2018

- New cases: 27% (26–28)
- Previously treated cases: 64% (63–66)

TB case notifications, 2018

- Total new and relapse: 12 832
- % tested with rapid diagnostics at time of diagnosis: 89%
- % with known HIV status: 95%
- % pulmonary: 91%
- % bacteriologically confirmed: 88%
- % children aged 0–14 years: 2%
- % women: 38%
- % men: 60%
- Total cases notified: 13 361

Universal health coverage and social protection

- TB treatment coverage (notified/estimated incidence), 2018: 100% (72–160)
- TB patients facing catastrophic total costs: 4% (3–6)
- TB case fatality ratio (estimated mortality/estimated incidence), 2018: 4% (3–6)
- Patients with known HIV status who are HIV-positive: 717
- % on antiretroviral therapy: 689

Drug-resistant TB care, 2018

- % of bacteriologically confirmed TB cases tested for rifampicin resistance: 94%
- % of previously treated cases: 90%
- Laboratory-confirmed cases*: MDR/RR-TB: 4 869, XDR-TB: 336
- Patients started on treatment**: MDR/RR-TB: 4 814, XDR-TB: 386
- MDR/RR-TB cases tested for resistance to second-line drugs: 4 384

Treatment success rate and cohort size

- New and relapse cases registered in 2017: 91% (589)
- Previously treated cases, excluding relapse, registered in 2017: 82% (250)
- MDR/RR-TB cases started on second-line treatment in 2016: 80% (6 260)
- XDR-TB cases started on second-line treatment in 2016: 48% (435)

TB preventive treatment, 2018

- % of HIV-positive people (newly enrolled in care) on preventive treatment: 53%
- % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment: 20% (19–22)

TB financing, 2019

- National TB budget (US$ millions): 134
- Funding source: 94% domestic, 6% international, 0% unfunded

** Ranges represent uncertainty intervals

* MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

** Calculated for pulmonary cases only

* Includes cases with unknown previous TB treatment history

** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed